Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia.

Romo-González M, Moreno-Paz S, García-Hernández V, Sánchez-Guijo F, Hernández-Hernández Á.

Antioxidants (Basel). 2020 Jan 15;9(1). pii: E74. doi: 10.3390/antiox9010074.

2.

Autologous adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistula: A randomized clinical trial with long-term follow-up.

Garcia-Arranz M, Garcia-Olmo D, Herreros MD, Gracia-Solana J, Guadalajara H, De la Portilla F, Baixauli J, Garcia-Garcia J, Ramirez JM, Sanchez-Guijo F, Prosper F; FISPAC Collaborative Group.

Stem Cells Transl Med. 2019 Dec 30. doi: 10.1002/sctm.19-0271. [Epub ahead of print]

3.

Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research.

Sánchez-Guijo F, García-Olmo D, Prósper F, Martínez S, Zapata A, Fernández-Avilés F, Toledo-Aral JJ, Torres M, Fariñas I, Badimón L, Labandeira-García JL, García-Sancho J, Moraleda JM; TerCel.

Cytotherapy. 2020 Jan;22(1):1-5. doi: 10.1016/j.jcyt.2019.11.001. Epub 2019 Dec 19. Review.

4.

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.

Colom-Fernández B, Kreutzman A, Marcos-Jiménez A, García-Gutiérrez V, Cuesta-Mateos C, Portero-Sainz I, Pérez-García Y, Casado LF, Sánchez-Guijo F, Martínez-López J, Ayala RM, Boqué C, Xicoy B, Montero I, Soto C, Paz R, Silva G, Vega-Piris L, Steegmann JL, Muñoz-Calleja C.

Front Pharmacol. 2019 Nov 25;10:1340. doi: 10.3389/fphar.2019.01340. eCollection 2019.

5.

Targeting the Immune System With Mesenchymal Stromal Cell-Derived Extracellular Vesicles: What Is the Cargo's Mechanism of Action?

Martin-Rufino JD, Espinosa-Lara N, Osugui L, Sanchez-Guijo F.

Front Bioeng Biotechnol. 2019 Nov 5;7:308. doi: 10.3389/fbioe.2019.00308. eCollection 2019. Review.

6.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Nov 21. doi: 10.1038/s41409-019-0740-9. [Epub ahead of print]

PMID:
31754251
7.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

8.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Oct 21. doi: 10.1038/s41409-019-0718-7. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Nov 21;:.

PMID:
31636397
9.

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

Soria-Juan B, Escacena N, Capilla-González V, Aguilera Y, Llanos L, Tejedo JR, Bedoya FJ, Juan V, De la Cuesta A, Ruiz-Salmerón R, Andreu E, Grochowicz L, Prósper F, Sánchez-Guijo F, Lozano FS, Miralles M, Del Río-Solá L, Castellanos G, Moraleda JM, Sackstein R, García-Arranz M, García-Olmo D, Martín F, Hmadcha A, Soria B; Collaborative Working Group “Noma Project Team”.

Front Immunol. 2019 Jun 4;10:1151. doi: 10.3389/fimmu.2019.01151. eCollection 2019.

10.

The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability.

Preciado S, Muntión S, Corchete LA, Ramos TL, de la Torre AG, Osugui L, Rico A, Espinosa-Lara N, Gastaca I, Díez-Campelo M, Del Cañizo C, Sánchez-Guijo F.

Stem Cells. 2019 Oct;37(10):1357-1368. doi: 10.1002/stem.3032. Epub 2019 Jun 11.

11.

Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.

Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, Caballero-Berrocal JC, Ortega R, Redondo AM, Sánchez-Guijo F, Muntión S, García-Martín L, Albarrán B, Alonso JM, Del Cañizo C, Hernández-Hernández Á, Díez-Campelo M.

Br J Haematol. 2019 Oct;187(1):93-104. doi: 10.1111/bjh.16013. Epub 2019 Jun 6.

PMID:
31172513
12.

Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency.

García-Tuñón I, Alonso-Pérez V, Vuelta E, Pérez-Ramos S, Herrero M, Méndez L, Hernández-Sánchez JM, Martín-Izquierdo M, Saldaña R, Sevilla J, Sánchez-Guijo F, Hernández-Rivas JM, Sánchez-Martín M.

PLoS One. 2019 May 9;14(5):e0216674. doi: 10.1371/journal.pone.0216674. eCollection 2019.

13.

Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.

Carrillo-Cruz E, García-Lozano JR, Márquez-Malaver FJ, Sánchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcárcel D, López-Godino O, Cuesta M, Parody R, López-Corral L, Alcoceba M, Caballero-Velázquez T, Rodríguez-Gil A, Bejarano-García JA, Ramos TL, Pérez-Simón JA.

Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1.

PMID:
31043390
14.

Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.

Blanco JF, Villarón EM, Pescador D, da Casa C, Gómez V, Redondo AM, López-Villar O, López-Parra M, Muntión S, Sánchez-Guijo F.

Stem Cell Res Ther. 2019 Feb 22;10(1):63. doi: 10.1186/s13287-019-1166-4.

15.

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.

Pérez-Fernández A, López-Ruano G, Prieto-Bermejo R, Ijurko C, Díez-Campelo M, Sánchez-Guijo F, Hernández-Hernández Á.

J Exp Clin Cancer Res. 2019 Feb 14;38(1):80. doi: 10.1186/s13046-019-1097-z.

16.

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD.

Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, Martín García E, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A.

Ocul Surf. 2019 Apr;17(2):285-294. doi: 10.1016/j.jtos.2019.01.001. Epub 2019 Jan 8.

PMID:
30630121
17.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0.

18.

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.

Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, Perez E, Lopez-Parra M, Avendaño A, Veiga A, Baile M, Arratibel N, Carrillo J, Vazquez L, Caballero MD, Gonzalez-Porras JR.

Bone Marrow Transplant. 2019 May;54(5):757-761. doi: 10.1038/s41409-018-0368-1. Epub 2018 Oct 24. No abstract available.

PMID:
30356164
19.

Human Bone Marrow Mesenchymal Stromal Cells Promote Bone Regeneration in a Xenogeneic Rabbit Model: A Preclinical Study.

Blanco JF, García-Briñon J, Benito-Garzón L, Pescador D, Muntión S, Sánchez-Guijo F.

Stem Cells Int. 2018 Jul 5;2018:7089484. doi: 10.1155/2018/7089484. eCollection 2018.

20.

Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.

Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA.

Eur J Haematol. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]

PMID:
30084111
21.

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II).

Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Núñez-Córdoba JM, López-Elío S, Andreu E, Sánchez-Guijo F, Aquerreta JD, Bondía JM, Valentí-Azcárate A, Del Consuelo Del Cañizo M, Villarón EM, Valentí-Nin JR, Prósper F.

J Transl Med. 2018 Jul 31;16(1):213. doi: 10.1186/s12967-018-1591-7.

22.

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. doi: 10.1016/j.bbmt.2018.07.015. Epub 2018 Jul 20.

23.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC).

Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28.

PMID:
29955943
24.

Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).

Martin-Rufino JD, Lozano FS, Redondo AM, Villaron EM, Rueda R, Fernandez-Samos R, Sanchez-Guijo F.

Stem Cell Res Ther. 2018 May 30;9(1):150. doi: 10.1186/s13287-018-0901-6.

25.

Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability.

Preciado S, Muntión S, Rico A, Pérez-Romasanta LA, Ramos TL, Ortega R, Borrajo J, Corchete LA, Rodríguez C, Díez-Campelo M, Sánchez-Abarca LI, Del Cañizo MC, Sánchez-Guijo F.

Biol Blood Marrow Transplant. 2018 Mar;24(3):443-451. doi: 10.1016/j.bbmt.2017.11.007. Epub 2017 Nov 16.

26.

Biocompatibility of two model elastin-like recombinamer-based hydrogels formed through physical or chemical cross-linking for various applications in tissue engineering and regenerative medicine.

Ibáñez-Fonseca A, Ramos TL, González de Torre I, Sánchez-Abarca LI, Muntión S, Arias FJ, Del Cañizo MC, Alonso M, Sánchez-Guijo F, Rodríguez-Cabello JC.

J Tissue Eng Regen Med. 2018 Mar;12(3):e1450-e1460. doi: 10.1002/term.2562. Epub 2017 Nov 26.

PMID:
28865091
27.

Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis.

Ramos TL, Sánchez-Abarca LI, Rosón-Burgo B, Redondo A, Rico A, Preciado S, Ortega R, Rodríguez C, Muntión S, Hernández-Hernández Á, De Las Rivas J, González M, González Porras JR, Del Cañizo C, Sánchez-Guijo F.

PLoS One. 2017 Aug 10;12(8):e0182470. doi: 10.1371/journal.pone.0182470. eCollection 2017.

28.

Regeneration of hyaline cartilage promoted by xenogeneic mesenchymal stromal cells embedded within elastin-like recombinamer-based bioactive hydrogels.

Pescador D, Ibáñez-Fonseca A, Sánchez-Guijo F, Briñón JG, Arias FJ, Muntión S, Hernández C, Girotti A, Alonso M, Del Cañizo MC, Rodríguez-Cabello JC, Blanco JF.

J Mater Sci Mater Med. 2017 Aug;28(8):115. doi: 10.1007/s10856-017-5928-1. Epub 2017 Jun 24.

PMID:
28647792
29.

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?

Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.

Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.

30.

Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2016 Nov 21;17(1):944.

31.

Assessment of dry eye in a GVHD murine model: Approximation through tear osmolarity measurement.

Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Ramos TL, Velasco A, Sánchez-Guijo F, Aijón J, Hernández-Galilea E.

Exp Eye Res. 2017 Jan;154:64-69. doi: 10.1016/j.exer.2016.11.004. Epub 2016 Nov 3.

PMID:
27818317
32.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA.

Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. No abstract available.

PMID:
27295268
33.

Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).

Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.

34.

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

Cervantes F, Correa JG, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S; CML Spanish Group (GELMC).

Ann Hematol. 2017 Jan;96(1):81-85. doi: 10.1007/s00277-016-2839-z. Epub 2016 Oct 8.

PMID:
27717993
35.

Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor.

Valencia J, Blanco B, Yáñez R, Vázquez M, Herrero Sánchez C, Fernández-García M, Rodríguez Serrano C, Pescador D, Blanco JF, Hernando-Rodríguez M, Sánchez-Guijo F, Lamana ML, Segovia JC, Vicente Á, Del Cañizo C, Zapata AG.

Cytotherapy. 2016 Oct;18(10):1297-311. doi: 10.1016/j.jcyt.2016.07.006.

PMID:
27637760
36.

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II).

Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM, Sánchez-Echenique C, Bondía JM, Aquerreta JD, Andreu EJ, Ornilla E, Villarón EM, Valentí-Azcárate A, Sánchez-Guijo F, Del Cañizo MC, Valentí-Nin JR, Prósper F.

J Transl Med. 2016 Aug 26;14(1):246. doi: 10.1186/s12967-016-0998-2.

37.

Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting.

Blanco B, Herrero-Sánchez MD, Rodríguez-Serrano C, García-Martínez ML, Blanco JF, Muntión S, García-Arranz M, Sánchez-Guijo F, Del Cañizo C.

Eur J Haematol. 2016 Dec;97(6):528-537. doi: 10.1111/ejh.12765. Epub 2016 Jun 1.

PMID:
27118602
38.

[Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].

García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL.

Med Clin (Barc). 2016 Jun 17;146(12):561.e1-8. doi: 10.1016/j.medcli.2016.02.022. Epub 2016 Apr 20. Spanish.

PMID:
27107729
39.

Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.

Muntión S, Ramos TL, Diez-Campelo M, Rosón B, Sánchez-Abarca LI, Misiewicz-Krzeminska I, Preciado S, Sarasquete ME, de Las Rivas J, González M, Sánchez-Guijo F, Del Cañizo MC.

PLoS One. 2016 Feb 2;11(2):e0146722. doi: 10.1371/journal.pone.0146722. eCollection 2016.

40.

MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry.

L Ramos T, Sánchez-Abarca LI, Muntión S, Preciado S, Puig N, López-Ruano G, Hernández-Hernández Á, Redondo A, Ortega R, Rodríguez C, Sánchez-Guijo F, del Cañizo C.

Cell Commun Signal. 2016 Jan 12;14:2. doi: 10.1186/s12964-015-0124-8.

41.

PTPN13 and β-Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche.

López-Ruano G, Prieto-Bermejo R, Ramos TL, San-Segundo L, Sánchez-Abarca LI, Sánchez-Guijo F, Pérez-Simón JA, Sánchez-Yagüe J, Llanillo M, Hernández-Hernández Á.

Stem Cell Reports. 2015 Oct 13;5(4):516-31. doi: 10.1016/j.stemcr.2015.08.003. Epub 2015 Sep 3.

42.

Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.

Ramos TL, Sánchez-Abarca LI, López-Ruano G, Muntión S, Preciado S, Hernández-Ruano M, Rosado B, de las Heras N, Chillón MC, Hernández-Hernández Á, González M, Sánchez-Guijo F, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):921-4. doi: 10.1016/j.leukres.2015.05.014. Epub 2015 Jun 11.

PMID:
26105049
43.

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome.

Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, Vazquez L, Caballero D, Del Cañizo C.

Leuk Res. 2015 Aug;39(8):828-34. doi: 10.1016/j.leukres.2015.05.003. Epub 2015 May 14.

PMID:
26009156
44.

Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.

Labrador J, López-Corral L, Vazquez L, Sánchez-Guijo F, Guerrero C, Sánchez-Barba M, Lozano FS, Alberca I, Del Cañizo MC, Caballero D, González-Porras JR.

Br J Haematol. 2015 Jun;169(5):719-25. doi: 10.1111/bjh.13344. Epub 2015 Mar 26.

PMID:
25817436
45.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
46.

Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis.

Cabral R, Caballero JC, Alonso S, Dávila J, Cabrero M, Caballero D, Vázquez L, Sánchez-Guijo F, López L, Cañizo MC, Mateos MV, González M.

Hematol Rep. 2014 Nov 19;6(4):5654. doi: 10.4081/hr.2014.5654. eCollection 2014 Nov 19.

47.

[Bone marrow microenvironment in chronic myeloid leukemia: implications for disease physiopathology and response to treatment].

Aristizábal JA, Chandia M, Del Cañizo MC, Sánchez-Guijo F.

Rev Med Chil. 2014 May;142(5):599-605. doi: 10.4067/S0034-98872014000500008. Review. Spanish.

48.

Transcriptomic portrait of human Mesenchymal Stromal/Stem Cells isolated from bone marrow and placenta.

Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J.

BMC Genomics. 2014 Oct 19;15:910. doi: 10.1186/1471-2164-15-910.

49.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

50.

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF, Garayoa M.

World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. Review.

Supplemental Content

Loading ...
Support Center